Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update

About this update from Valerio Therapeutics

VILLEJUIF, France, July 16, 2026 --( BUSINESS WIRE )--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics (" Valerio " or the " Company "), today announces that it has entered into a binding term-sheet with Abivax SA (" Abivax "), setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement. In connection with this collaboration, Valerio and Abivax will work together to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases, leveraging Abivax's expertise in this area together with Valerio's targeted technology platforms. The collaboration will include the generation, manufacturing and preclinical evaluation of research candidates. The candidates will be evaluated for their therapeutic potential and may be further developed by Abivax. Under the terms of the binding term-sheet, Valerio will receive an upfront payment up to approximately €2.4 million and would be eligible to receive development and commercial milestone payments, as well as royalties on net sales and sublicensing revenues, subject to the execution of the definitive co-ownership and license agreement and the achievement of specified milestones and other terms. "This collaboration brings together two highly complementary scientific capabilities: Abivax's expertise in immune-mediated inflammatory diseases and Valerio's advanced technology platforms. We believe this collaboration creates an exciting opportunity to explore innovative therapeutic approaches that leverage complementary expertise. We look forward to working closely with the Abivax team to advance this research and evaluate its potential to address important unmet medical needs for patients," said Gilles Besin, Ph.D., the Company's Chief Executive Officer.

View stock analysis, news, and events for Valerio Therapeutics